ES2186811T3 - Derivados de feniltiazol con propiedades anti-virus herpes. - Google Patents

Derivados de feniltiazol con propiedades anti-virus herpes.

Info

Publication number
ES2186811T3
ES2186811T3 ES96945567T ES96945567T ES2186811T3 ES 2186811 T3 ES2186811 T3 ES 2186811T3 ES 96945567 T ES96945567 T ES 96945567T ES 96945567 T ES96945567 T ES 96945567T ES 2186811 T3 ES2186811 T3 ES 2186811T3
Authority
ES
Spain
Prior art keywords
herpes
derivatives
phenyltiazol
properties
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945567T
Other languages
English (en)
Inventor
James J Crute
Anne-Marie Fauche
Christopher A Grygon
Karl D Hargrave
Bruno Simoneau
Bounkham Thavonekham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Canada Ltd, Boehringer Ingelheim Pharmaceuticals Inc filed Critical BOEHRINGER INGELHEIM PHARMA
Application granted granted Critical
Publication of ES2186811T3 publication Critical patent/ES2186811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A METODOS PARA INHIBIR LA REPLICACION DE HERPES Y PARA TRATAR INFECCIONES POR HERPES EN UN MAMIFERO MEDIANTE INHIBICION DEL COMPLEJO ENZIMATICO HELICASA-PRIMASA DEL HERPES. ESTA INVENCION TAMBIEN SE REFIERE A DERIVADOS TIAZOLILFENILO DE FORMULA (G) QUE INHIBEN EL COMPLEJO HELICASAPRIMASA DEL HERPES Y A COMPOSICIONES FARMACEUTICAS QUE INCLUYEN LOS DERIVADOS TIAZOLILFENILO, A METODOS PARA USAR Y METODOS PARA PRODUCIR LOS DERIVADOS TIAZOLILFENILO. EN LA FORMULA (G), R Y Z SON COMO SE DEFINE EN LA APLICACION EN LA QUE Z ES EL RASGO CARACTERISTICO.
ES96945567T 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes. Expired - Lifetime ES2186811T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US943395P 1995-12-29 1995-12-29
US2320996P 1996-08-02 1996-08-02

Publications (1)

Publication Number Publication Date
ES2186811T3 true ES2186811T3 (es) 2003-05-16

Family

ID=26679472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945567T Expired - Lifetime ES2186811T3 (es) 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes.

Country Status (26)

Country Link
US (3) US6057451A (es)
EP (1) EP0871619B1 (es)
JP (1) JP4327249B2 (es)
KR (1) KR19990076964A (es)
AR (1) AR037060A1 (es)
AT (1) ATE227279T1 (es)
AU (1) AU1682897A (es)
BG (1) BG102583A (es)
BR (1) BR9612435A (es)
CA (1) CA2192433C (es)
CZ (1) CZ207298A3 (es)
DE (1) DE69624728T2 (es)
DK (1) DK0871619T3 (es)
EA (1) EA199800611A1 (es)
EE (1) EE9800154A (es)
ES (1) ES2186811T3 (es)
HU (1) HUP9902341A2 (es)
IL (1) IL124436A0 (es)
MX (1) MX9805291A (es)
NO (1) NO982950L (es)
NZ (1) NZ331104A (es)
PL (1) PL327582A1 (es)
PT (1) PT871619E (es)
SK (1) SK89398A3 (es)
TR (1) TR199801244T2 (es)
WO (1) WO1997024343A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2000026197A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
CN1372548A (zh) * 1999-07-01 2002-10-02 味之素株式会社 杂环化合物及其医药用途
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2001096874A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
MXPA03001535A (es) * 2000-08-21 2004-12-13 Pacific Corp Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos.
DE60120421T2 (de) * 2000-08-21 2006-12-28 Pacific Corp. Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
US20030203944A1 (en) * 2000-08-21 2003-10-30 Suh Young Ger Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
KR20030045180A (ko) * 2000-11-10 2003-06-09 야마노우치세이야쿠 가부시키가이샤 아미드 유도체
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
EP1487796A4 (en) * 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
AU2003235889A1 (en) * 2002-05-09 2003-11-11 Rational Drug Design Laboratories Amide derivatives
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
KR101154163B1 (ko) * 2003-01-27 2012-06-14 아스텔라스세이야쿠 가부시키가이샤 티아졸 유도체 및 ｖａｐ-1 저해제로서의 용도
CA2520957C (en) * 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
NZ549787A (en) 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
JP5011739B2 (ja) * 2005-02-03 2012-08-29 アステラス製薬株式会社 テトラヒドロ−２ｈ−チオピラン−４−カルボキサミド誘導体を含有する医薬組成物
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP1910279A2 (en) * 2005-06-24 2008-04-16 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
BRPI0715729A2 (pt) * 2006-08-30 2013-09-24 Hoffmann La Roche inibidores para glyt-1
WO2008154601A1 (en) * 2007-06-12 2008-12-18 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
EP2351565A1 (en) 2008-10-20 2011-08-03 Astellas Pharma Inc. Medicine for preventing or treating pain related to herpes zoster
WO2010077836A2 (en) * 2009-01-05 2010-07-08 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the cb2 receptor
WO2011047390A2 (en) 2009-10-16 2011-04-21 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis c virus
WO2012113920A1 (en) 2011-02-24 2012-08-30 Katholieke Universiteit Leuven Arylsulfone derivatives with activity against human betaherpesviruses
KR101399484B1 (ko) * 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
UY35772A (es) 2013-10-14 2015-05-29 Bayer Cropscience Ag Nuevos compuestos plaguicidas
CN107438435B (zh) * 2014-11-10 2020-12-04 埃弗里斯生物有限责任公司 抗-hcmv组合物和方法
EP3256461B1 (en) * 2015-02-13 2023-09-13 Azienda Ospedaliera Universitaria Senese Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases
AU2017245679B2 (en) 2016-04-06 2021-07-01 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
EP3568390B1 (en) * 2017-01-10 2024-03-06 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
EP4209491A1 (en) 2017-10-05 2023-07-12 Innovative Molecules GmbH Enantiomers of substituted thiazoles as antiviral compounds
WO2020010252A1 (en) 2018-07-05 2020-01-09 Daiichi Sankyo Company, Limited Fused ring compound having urea structure
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
US11377425B1 (en) * 2018-12-19 2022-07-05 Leo Pharma A/S Small molecule modulators of IL-17
TW202126649A (zh) 2019-09-26 2021-07-16 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629247A (en) * 1969-06-06 1971-12-21 Pfizer Thiazoline and 5 6-dihydro-4h-1 3-thiazine antiviral agents
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH075579B2 (ja) * 1986-09-01 1995-01-25 吉富製薬株式会社 アミノチアゾ−ル化合物
MX174210B (es) * 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
AU1347292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression of viral genes and other genes
GB9125970D0 (en) * 1991-12-06 1992-02-05 Fujisawa Pharmaceutical Co New compounds
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
GB2276164A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
WO1999042455A1 (en) * 1998-02-19 1999-08-26 Tularik Inc. Antiviral agents

Also Published As

Publication number Publication date
AR037060A1 (es) 2004-10-20
KR19990076964A (ko) 1999-10-25
NO982950D0 (no) 1998-06-25
PL327582A1 (en) 1998-12-21
US6458959B1 (en) 2002-10-01
PT871619E (pt) 2003-03-31
DE69624728D1 (de) 2002-12-12
ATE227279T1 (de) 2002-11-15
EP0871619B1 (en) 2002-11-06
BR9612435A (pt) 1999-07-13
DK0871619T3 (da) 2003-03-03
DE69624728T2 (de) 2003-07-10
AU1682897A (en) 1997-07-28
EE9800154A (et) 1998-12-15
NZ331104A (en) 2000-03-27
CZ207298A3 (cs) 1998-11-11
JP2000502702A (ja) 2000-03-07
US6348477B1 (en) 2002-02-19
WO1997024343A1 (en) 1997-07-10
US6057451A (en) 2000-05-02
EA199800611A1 (ru) 1999-04-29
CA2192433A1 (en) 1997-06-30
HUP9902341A2 (hu) 1999-10-28
TR199801244T2 (xx) 1998-12-21
EP0871619A1 (en) 1998-10-21
MX9805291A (es) 1998-10-31
NO982950L (no) 1998-06-25
SK89398A3 (en) 1998-11-04
BG102583A (en) 1999-06-30
IL124436A0 (en) 1998-12-06
JP4327249B2 (ja) 2009-09-09
CA2192433C (en) 2008-01-08

Similar Documents

Publication Publication Date Title
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
BR0213129A (pt) Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
MX9304359A (es) Derivados de rapamicina.
UY25330A1 (es) Nuevos macrólidos
ES2183937T3 (es) Inhibidores de la adhesion celular.
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
UY25780A1 (es) Nuevos antibióticos macrólidos
MX9304361A (es) Derivados de rapamicina.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
ES2184126T3 (es) Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz.